TRDA
Price:
$18.8
Market Cap:
$703.50M
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporate...[Read more]
Industry
Biotechnology
IPO Date
2021-10-29
Stock Exchange
NASDAQ
Ticker
TRDA
According to Entrada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 686.76M. This represents a change of 39.85% compared to the average of 491.07M of the last 4 quarters.
The mean historical Enterprise Value of Entrada Therapeutics, Inc. over the last ten years is 517.53M. The current 686.76M Enterprise Value has changed 13.17% with respect to the historical average. Over the past ten years (40 quarters), TRDA's Enterprise Value was at its highest in in the September 2024 quarter at 632.53M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.
Average
517.53M
Median
499.36M
Minimum
243.50M
Maximum
731.56M
Discovering the peaks and valleys of Entrada Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 65.86%
Maximum Annual Enterprise Value = 731.56M
Minimum Annual Increase = -65.67%
Minimum Annual Enterprise Value = 243.50M
Year | Enterprise Value | Change |
---|---|---|
2023 | 499.36M | 23.64% |
2022 | 403.86M | 65.86% |
2021 | 243.50M | -65.67% |
2020 | 709.36M | -3.03% |
The current Enterprise Value of Entrada Therapeutics, Inc. (TRDA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
382.24M
5-year avg
517.53M
10-year avg
517.53M
Entrada Therapeutics, Inc.’s Enterprise Value is greater than Molecular Partners AG (130.63M), greater than PMV Pharmaceuticals, Inc. (47.77M), greater than Monte Rosa Therapeutics, Inc. (439.72M), greater than Vigil Neuroscience, Inc. (98.69M), greater than Third Harmonic Bio, Inc. (269.19M), greater than Cullinan Oncology, Inc. (630.54M), less than Edgewise Therapeutics, Inc. (3.01B), greater than Rallybio Corporation (17.23M), less than Crinetics Pharmaceuticals, Inc. (4.93B), less than Centessa Pharmaceuticals plc (1.75B), less than Disc Medicine, Inc. (1.74B), greater than Larimar Therapeutics, Inc. (363.34M), greater than PepGen Inc. (120.50M), less than Tyra Biosciences, Inc. (703.47M), less than Pharvaris N.V. (850.00M), less than Eliem Therapeutics, Inc. (0), greater than Genenta Science S.p.A. (119.64M), greater than Opthea Limited (78.68M), greater than Pardes Biosciences, Inc. (514.42M), greater than null (75.90M),
Company | Enterprise Value | Market cap |
---|---|---|
130.63M | $216.81M | |
47.77M | $83.31M | |
439.72M | $521.60M | |
98.69M | $130.41M | |
269.19M | $561.88M | |
630.54M | $730.17M | |
3.01B | $3.05B | |
17.23M | $42.32M | |
4.93B | $5.20B | |
1.75B | $2.06B | |
1.74B | $1.93B | |
363.34M | $393.05M | |
120.50M | $143.75M | |
703.47M | $801.05M | |
850.00M | $1.20B | |
0 | $342.68M | |
119.64M | $85.85M | |
78.68M | $486.27M | |
514.42M | $135.19M | |
75.90M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Entrada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Entrada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Entrada Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Entrada Therapeutics, Inc. (TRDA)?
What is the 3-year average Enterprise Value for Entrada Therapeutics, Inc. (TRDA)?
What is the 5-year average Enterprise Value for Entrada Therapeutics, Inc. (TRDA)?
How does the current Enterprise Value for Entrada Therapeutics, Inc. (TRDA) compare to its historical average?